JWH-138: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 25: | Line 25: | ||
{{stub}} | {{stub}} | ||
<gallery> | |||
File:JWH-138_structure.png|JWH-138 structure | |||
File:D3-THC-C8_structure.png|D3-THC-C8 structure | |||
File:d9-THC-C8_structure.png|d9-THC-C8 structure | |||
</gallery> | |||
Latest revision as of 02:14, 18 February 2025
JWH-138 is a synthetic cannabinoid from the JWH series. It was discovered by and named after Dr. John W. Huffman. JWH-138 has analgesic effects and is used in scientific research. It is not currently approved for medical use.
Chemistry[edit]
JWH-138 is a member of the JWH series of synthetic cannabinoids. It is a complex organic compound with the molecular formula C23H25NO. The compound is made up of a naphthoyl group, a cyclohexylmethyl group, and a hydroxyl group. The naphthoyl group is attached to the cyclohexylmethyl group by a ketone bridge, and the hydroxyl group is attached to the naphthoyl group.
Pharmacology[edit]
JWH-138 acts as a potent agonist at the CB1 receptor and CB2 receptor, the two main cannabinoid receptors in the body. It has a binding affinity of 9.0 nM at CB1 and 2.94 nM at CB2. The compound's effects are primarily mediated by its action on these receptors.
Effects[edit]
The effects of JWH-138 are similar to those of other cannabinoids. It produces analgesic effects, and may also have anti-inflammatory and neuroprotective effects. However, the compound is not currently approved for medical use, and its safety profile is not well established.
Legal status[edit]
JWH-138 is a controlled substance in many countries, including the United States, where it is classified as a Schedule I drug under the Controlled Substances Act.


